Skip to main content

Table 1 Trials conducted in China

From: Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis

Study ID Location Drug Combination therapy Participants in placebo groups, N Average age, years Gender, male, % Duration of diabetes, years Baseline HbA1c, % Change of HbA1c in placebo groups, % Duration, weeks Jadad score
Yang [11] China Sitagliptin Metformin 198 55 55 7.30 8.50 -0.14 24 5
NCT01076088 [12] China Sitagliptin None 127 40 68 / 8.97 -0.59 24 /
Metformin 126 57 55 8.69 -1.29
Metformin 124 49 60 8.67 -1.56
NCT01177384 [13] China Sitagliptin Acarbose 189 57 51 / 8.08 -0.14 24 /
Mohan [14] China Sitagliptin / 82 51 60 1.70 8.60 -0.20 18 5
Pan [6] China Vildagliptin Metformin 144 54 46 5.15 8.01 -0.54 24 3
Yang [15] China Vildagliptin Glimepiride 136 59 58 6.90 8.70 -0.20 24 4
Zeng [16] China Linagliptin Metformin & sulphonylurea 48 57 52 >5 8.13 0.08 24 3
NCT01289119 [17] China Alogliptin None 93 53 58 2.12 / -0.42 16 /
Metformin 98 53 49 5.33 -0.22
Pioglitazone 63 52 62 4.85 -0.25
Chen [18] China Linagliptin / 88 54 59 / 8.09 -0.25 24 4
Ning [19] China Vildagliptin Insulin 118 58.5 55 11.4 8.6 -0.22 24 5